Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study

OBJECTIVE: To test the safety and efficacy of exenatide once weekly (EQW) compared with metformin (MET), pioglitazone (PIO), and sitagliptin (SITA) over 26 weeks, in suboptimally treated (diet and exercise) drug-naive patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Patients were randomiz...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Russell-Jones, David, Cuddihy, Robert M., Hanefeld, Markolf, Kumar, Ajay, González, Jose G., Chan, Melanie, Wolka, Anne M., Boardman, Marilyn K.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Diabetes Association 2012
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3263915/
https://ncbi.nlm.nih.gov/pubmed/22210563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc11-1107
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky